“Our investigations are a very first step, in which we have shown that labelling cells with hepatitis liver failure works, in principle, in living organisms,” emphasises biochemist Prof Andrea Rentmeister. “What matters here is that the substrate is diet for liver failure rapidly in the organism and that it binds exclusively to the cells to be studied.” The next crucial steps will be to test how many cells are needed to signs of bad liver function a sufficiently strong signal and whether the method can also be used to visualise cells that move within the organism — in particular immune system cells. If the approach continues to liver protection medicine successful, the technique may become important for future research into immunotherapies in which the body’s own immune cells are effects of liver failure modified in the laboratory so that they can combat a specific disease. Such therapies are already being used medications that cause liver damage cancer treatment and have the potential to help treat inflammatory diseases as well. Imaging could help develop and improve such treatments.